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Demonstration of early functional compromise of
bone marrow derived hematopoietic progenitor
cells during bovine neonatal pancytopenia
through in vitro culture of bone marrow biopsies
Eleanor Laming1, Eleonora Melzi1, Sandra FE Scholes2, Maira Connelly1, Charlotte R Bell3, Keith T Ballingall1,
Mark P Dagleish1, Mara S Rocchi1 and Kim Willoughby1*
Abstract
Background: Bovine neonatal pancytopenia (BNP) is a syndrome characterised by thrombocytopenia associated
with marked bone marrow destruction in calves, widely reported since 2007 in several European countries and
since 2011 in New Zealand. The disease is epidemiologically associated with the use of an inactivated bovine virus
diarrhoea (BVD) vaccine and is currently considered to be caused by absorption of colostral antibody produced by
some vaccinated cows (“BNP dams”). Alloantibodies capable of binding to the leukocyte surface have been
detected in BNP dams and antibodies recognising bovine MHC class I and β-2-microglobulin have been detected
in vaccinated cattle. In this study, calves were challenged with pooled colostrum collected from BNP dams or from
non-BNP dams and their bone marrow hematopoietic progenitor cells (HPC) cultured in vitro from sternal biopsies
taken at 24 hours and 6 days post-challenge.
Results: Clonogenic assay demonstrated that CFU-GEMM (colony forming unit-granulocyte/erythroid/macrophage/
megakaryocyte; pluripotential progenitor cell) colony development was compromised from HPCs harvested as early
as 24 hour post-challenge. By 6 days post challenge, HPCs harvested from challenged calves failed to develop
CFU-E (erythroid) colonies and the development of both CFU-GEMM and CFU-GM (granulocyte/macrophage) was
markedly reduced.
Conclusion: This study suggests that the bone marrow pathology and clinical signs associated with BNP are
related to an insult which compromises the pluripotential progenitor cell within the first 24 hours of life but that
this does not initially include all cell types.
Keywords: Bovine neonatal pancytopaenia, BNP, Colostrum hematopoietic progenitor cells, BM-HPCs, Pluripotential
Background
Bovine neonatal pancytopenia (BNP) is a recently emerged
disease of young calves which has been recognised in a
number of European countries since 2007 and in New
Zealand in 2011 [1-5]. The major clinical signs are asso-
ciated with thrombocytopenia and include petechiation
and external and/or internal haemorrhage. Other haem-
atological abnormalities are described in clinical cases,
including leukopenia with both lymphocyte and neutro-
phil depletion. The underlying lesion is a dramatic bone
marrow injury with depletion of hematopoietic cells and
their precursors. There is an association with maternal
vaccination with an inactivated bovine virus diarrhoea
(BVD) vaccine (Pregsure BVD, Pfizer) [6,7]; which was
voluntarily withdrawn by the manufacturer in Europe in
2010, but BNP cases continue in calves born to or ingest-
ing colostrum derived from some vaccinated animals. The
syndrome can be reproduced by feeding of colostrum
from cows which have borne affected calves (BNP dams)
to unrelated calves [8-10], and disease can be prevented
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by colostrum substitution [11]. While individual colostra
have a more variable outcome in terms of development of
BNP [8,9], the use of pooled colostrum from a number of
BNP dams produces a more reliable outcome with a high
proportion (80-100%) of calves developing BNP or its typ-
ical clinicopathological features [10].
Antibodies present in serum of BNP dams have been
shown to be capable of binding to peripheral leukocytes
and to cells in bone marrow smears of unrelated normal
calves [12] and were detected bound to leukocytes of
affected calves [9,13]. Such studies support the hypothesis
that maternally derived colostral alloantibody targeting a
bovine antigen (or antigens) causes the bone marrow path-
ology in calves. While the identity of the target antigen(s) is
unconfirmed, evidence supporting the presence of anti-
bovine MHC Class I antibodies in BNP dams [14] and in-
duction of anti-bovine MHC Class I antibodies by the
implicated vaccine has recently been described [15].
While no linkage to MHC-class II nor factor XI has
been detected in affected calves there is some evidence
that within herds, specific groups or lines of animals
may be more frequently affected, suggesting that some
cows are more at risk of BNP-associated alloantibody
production due to either intrinsic factors or to inter-
action between the pregnant cow and its fetus [16,17].
The lack of an animal model, reliance on clinical cases
and the requirement to use colostral challenge of calves
to investigate the disease has severely limited the oppor-
tunities for systematic investigation. We describe here a
pilot study on the utility of bone marrow hematopoietic
progenitor cell (BM-HPC) cultures to assess the func-
tional compromise of harvested bovine BM-HPCs at 24
hours and 6 days post challenge with either pooled BNP
dam colostrum or pooled normal colostrum.
Methods
Animals
Four male Holstein Friesian colostrum deprived calves
were sourced over a period of 1 week from a single dairy
farm and fed either challenge (n=2; calves W and Y) or
control (n=2; calves X and Z) colostrum pools. To en-
sure that the calves represented a broad range of MHC
genotypes, each calf was genotyped at the highly poly-
morphic MHC class II DRB3 [16]. The MHC genotypes
of each calf were as follows; W, DRB3*1001, DRB3*1201;
X, DRB3*1001, DRB3*1501; Y, DRB3*0101, DRB3*1001
and Z, DRB3*1201, DRB3*1201.
Colostrum
The challenge pool consisted of a standardised colostrum
pool collected from 9 previously identified BNP dams.
Challenge calves were fed 2.15 litres of this colostrum pool
within 6 hours of birth. Control calves were fed a similarly
constituted pool collected from 9 dams sourced from a
BVDV free, BVDV unvaccinated farm where no cases of
BNP had been observed. All calves were bottle fed colos-
trum to aid closure of the rumenoreticular groove and op-
timise antibody absorption. In a previous study we
confirmed that this challenge pool induces BNP (data not
shown; submitted for publication).
Clinical scoring
A defined clinical scoring system was used to determine the
end point of the experiment. Parameters measured included
demeanour, rectal temperature, heart and respiratory rate,
presence and duration of petechiation or other abnormal
bleeding, packed cell volume (PCV, by microhematocrit)
and manual thrombocyte count based on inspection of a
stained blood smear (Reastain Quick Diff, Reagena), deter-
mination of the average number of platelets in 5 oil
immersion fields (100×) and multiplication to generate an
estimated thrombocyte count expressed as ×109/litre. All
experimental protocols involving animals were approved by
the Moredun Research Institute Animal Experiments &
Ethical Review Committee and authorised under the UK
Animals (Scientific Procedures) Act 1986.
Analysis of blood samples
Blood samples were taken by jugular venepuncture using a
needle and syringe to avoid artefactual thrombocyte
clumping. Samples were taken pre-challenge, then at 4,8,12
and 24 hours post-colostrum feeding and daily thereafter.
Analysis of colostrum deprivation and subsequent absorp-
tion of colostrum was assessed by determination of serum
gamma glutamyltransferase (γGT) as a passive marker.
Routine haematology was performed (including erythro-
cyte, thrombocyte and total leukocyte counts, MVC,
MCHC and white blood cell differential count) at a com-
mercial laboratory (SAC Veterinary Services, Penicuik).
Quantification of lymphocyte subset depletion was
performed using an indirect fluorescence staining and
flow cytometric analysis as previously described [18].
Erythrocytes were lysed using an ammonium-chloride
based reagent [19] and leukocytes washed and resus-
pended in FACS buffer (PBS, 5% heath inactivated FBS,
0.02%NaN3) for the labelling with the following anti-
bodies: IgG1 and IgG2a isotype controls (Moredun, UK,
2 μg/ml), anti bovine CD3 (VMRD, USA, 1 μg/ml), CD4
(VMRD, USA, 2 μg/ml), CD8 (ILRI, Kenya, 1 μg/ml) and
γ/δ TCR (VMRD, USA, 1.25 μg/ml), anti bovine NK p46
(Serotec, UK, 1 μg/ml), anti bovine CD25 (VMRD, USA,
1 μg/ml), anti bovine CD21 (Serotec, UK, 1 μg/ml ), and
anti bovine SIRP-α (monocytes) (ILRI, Kenya, 1 μg/ml).
Labelling was detected with goat-anti mouse IgG Alexa
488 conjugate (Invitrogen UK, 1 μg/ml). Up to 20,000
events/ per samples were acquired with a CyAn ADP flow
cytometer (Beckman Coulter, USA) and analysed with
Summit software (Dako, USA).
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Bone marrow biopsy
We performed extensive assessment of the preferred site
(femur or sternum) and method (core biopsy or aspirate)
for bone marrow sampling using similarly aged calves
euthanased for other reasons. We found that the most reli-
able site of bone marrow biopsy was the sternum, and that
a core biopsy was the most reliable and reproducible
method for both histopathological examination and for
collection of undamaged, viable cells in the numbers
required for the clonogenic assay described below. Evi-
dence that approach used was effective included good reli-
able harvests of viable cells for culture and no evidence of
cell damage or artefactual depletion in the histological pre-
parations. Sternal bone marrow biopsies were taken under
reversible sedation (intravenous 10 μg/kg medetomidine
hydrochloride, reversed with atipamazole) and local anal-
gesia (20 mg lignocaine hydrochloride with adrenaline and
5 mg of bupivicaine hydrochloride) at 24 hours and 6 days
post challenge using a 0.5 cm diameter trephine needle
(Rocket Medical, Washington, UK). The animals were
closely monitored after biopsy for signs of discomfort, pain,
bleeding or infection; none were detected.
Clonogenic assay of hematopoietic progenitor cells
A protocol based on a previously described method [20]
was followed with some minor modifications. Briefly,
following the biopsy procedure, the bone marrow core
was released from the needle and placed immediately
into a universal container with 6ml of collection medium
(CM: Iscove’s Modified Dulbecco’s Medium (IMDM)
supplemented with 10% heat inactivated FBS, 8 mM
L-glutamine, 100 IU penicillin/100 μg streptomycin per
ml, 1.25 μg/ml of amphotericin B and 20 IU/ml of lith-
ium heparin) and placed on a rotary suspension mixer
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Figure 1 Results of biochemical and haematological testing. The scale on the X- axis for all graphs is in hours for time points 0,4,8,12 and 24
and for days 2–12 thereafter. The scale on the Y-axis is as appropriate for the parameter measured (see appropriate sub-legend). (a) results of
testing for GGT (iu/litre) to demonstrate adequate colostral absorption. (b) PCV (%): no difference was observed between challenge (X,Z) and
control (W,Y) calves. (c) Erythrocyte count (x1012/litre): no difference was observed between challenge (X,Z) and control (W,Y) calves. (d)
Thrombocyte count (x109/litre): challenge calves (W and Y) demonstrate a marked reduction in thrombocyte counts when compared to controls
(X and Z). (e) Leukocyte count (x109/litre): challenge calves (W and Y) demonstrate a marked reduction in leukocyte counts when compared to
controls (X and Z). (f) Mature neutrophil count (x109/litre): no difference was observed between challenge (X,Z) and control (W,Y) calves. (g) Band
(immature) neutrophil count (x109/litre): no difference was observed between challenge (X,Z) and control (W,Y) calves. (h) Lymphocyte count
(x109/litre): challenge calves (W and Y) demonstrate a marked reduction in lymphocyte counts when compared to controls (X and Z). Note: These
results have no level of statistical significance indicated as there are only 2 animals in each group. Values are only available until day 6 for calf Z
which was euthanased for welfare reasons unrelated to the experiment.
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for 30 minutes at room temperature (RT). The released
cell suspension was harvested and the residual biopsy
core fixed in formalin and, following decalcification,
routinely processed for histological examination (see
below). The cell suspension was layered onto 6 ml of
Lymphoprep (Axis-Shield, UK) density gradient separ-
ation medium (density 1.077 g/ml) and centrifuged at
1175 g for 30 minutes at 15°C. The interface (mono-
nuclear cell layer), was collected and washed 3 times
with washing medium (WM: as CM above but without
heparin), with centrifugation at 250 g for 10 minutes at
4°C between each wash. After the final wash, the cell
pellet was resuspended in 1ml WM.
A viable cell count was performed on the final cell sus-
pension using 0.2% nigrosin and a haemocytometer. The
concentration was adjusted to 1 × 106 live cells per ml in
WM. The cell suspension was then diluted 1/10 in a com-
mercial methylcellulose culture medium containing human
recombinant erythropoietin (MethocultW H4034 Optimum
with EPO, Stemcell Technologies, UK) to achieve a final
concentration of 1 × 105 cells per ml. Granulocyte/macro-
phage colony-stimulating factor (rboGM-CSF expressed
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Figure 2 Changes in the relative percentages of peripheral blood mononuclear cells following control or challenge colostrum
administration. Relative percentages were calculated as increase/decrease in the proportion of cells normalised to the pre-administration values
(100%). Time points (X axis) were as follow: 1: pre-challenge; 2: 4 hours post challenge; 3: 8 hours; 4: 12 hours; 5: 24 hours; 7: day 3; 9: day 5; 11:
day 7; 13: day 9 and 15: day 11. Animal Z was humanely euthanized at time point 11. Blue lines: control animals (triangle calf X, diamond calf Z);
red lines: challenged animals (square calf W, triangle calf Y).
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in CHO cells using a previously defined protocol for
recombinant cytokine expression [21], a gift from Prof.
G. Entrican, Moredun) was added to the suspension at
the previously determined optimum dilution for DC cul-
ture, according to the method of Werling et al. [22]. The
media and cells were vortex mixed thoroughly and left to
stand for 10 minutes to allow air bubbles to dissipate prior
to plating. Each sample was plated in duplicate, adding 1.1
ml to each of two 35 mm culture dishes using 3 ml syr-
inges and 16-gauge blunt-ended needles (Stemcell tech-
nologies, UK). On one occasion (calf Y day 6) insufficient
cell numbers were obtained for 2 dishes and a single dish
was prepared. Quadrants were marked out and numbered
on the underside of each dish to facilitate colony counting.
The two dishes were placed in a 100 mm culture dish with
a third uncovered dish containing sterile distilled water,
and placed in a humidified incubator at 37°C with 5% CO2.
Colony scoring
Prior to the study, the method for identifying colonies
was developed using bone marrow biopsy material op-
portunistically obtained from calves euthanased for other
reasons. Preliminary colony identification was made
through assessment of morphological characteristics of
the colony itself and of the single cells of which it was
composed. This assessment was confirmed by picking
up the colony and examination of a stained smear and/
or cytospin preparation.
For the study samples, microscopic examination of the
cultures was performed using a 60 mm gridded scoring
dish as a template to facilitate counting. Cell colonies were
counted and typed as CFU-GEMM, CFU-E and CFU-GM.
As per previous studies [23-25] clusters of cells were con-
sidered colonies for CFU-GM when more than 40 cells
were counted at day 7 and for CFU-E when more
than 8 haemoglobinised cells were counted at day 5.
CFU-GEMM are considered multilineage colonies with
the largest number of cells but are not previously char-
acterised in cattle; we counted colonies of greater than
10 cells at day 2 and greater than 100 cells at day 7.
Results
Hematology
Calves which received challenge colostrum developed
marked thrombocytopenia by day 6 and marked lymphope-
nia between 4 and 8 hours post-challenge (Figure 1), con-
sistent with the pre-clinical stages of BNP. These alterations
persisted until euthanasia. No abnormalities were observed
in the control animals.
Peripheral lymphocyte depletion
Blood samples collected from the two challenged and two
control animals were typed for specific lymphocyte subsets
and the number of population-specific cells displayed as
percentage increase or decrease from the initial pre-
challenge values (Figure 2). For all but the CD21+ve sub-
population (B cells) the data obtained in the unchallenged
animals was remarkably consistent and showed only minor
changes over time. The challenged animals displayed a lar-
ger variability in their subpopulation values however, and a
clear reduction in the proportion of CD25+ve, CD21+ve and
γ/δ TCR+ve cells was observed immediately after challenge.
CD3, CD4 and CD8+ve cells did not show a similar decline;
on the contrary we noticed an increase in CD4+ve and
CD8+ve relative percentages towards the later stages of the
observation period. The values of NK cells and SIRP-α
positive cells (monocytes) were too variable to identify
specific trends.
Clinical and post mortem findings
Petechiation and bleeding from the ear tag was observed
in both challenged calves from day 7 (Figure 3a) and eu-
thanasia was performed in accordance with the clinical
scoring system at day 11 (calf W) and 12 (calf Y). Post-
mortem examination (PME) demonstrated gross lesions
consistent with BNP (Figure 3b) and histopathological
Figure 3 a: Haemorrhage from the ear tag of challenged calf Y
12 days post challenge. b: Petechiation of the laryngeal and
pharyngeal tissues at necropsy.
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examination of bone marrow confirmed both challenged
calves had lesions of trilineage hypoplasia at the time of
euthanasia (Figure 4). The control calves were not clinic-
ally affected, did not develop any haematological abnormal-
ities, bone marrow lesions, nor were gross or histological
lesions observed at necropsy. These findings confirmed the
induction of BNP in both challenge calves.
Histopathology: sternal bone marrow biopsy
All sternal biopsy cores contained substantial amounts
of medullary intertrabecular tissue. No difference was
detectable between the challenged calves and the control
calves at day 1, with moderately abundant myeloid and
erythroid series cells and megakaryocytes at varying
stages of maturation (Figure 4). In contrast, in the chal-
lenge calves at day 6 there were marked reductions in
the numbers of megakaryocytes, which were mostly ma-
ture (stage 3), and the myeloid and erythroid series cells
were mainly represented by mature neutrophils and
eosinophils and by late normoblasts (Figure 4), whereas
the haematopoietic cell density had increased in both
control calves compared with day 1.
Hematopoietic progenitor cell cultures
BM-HPC cultures demonstrated normal colony develop-
ment in the control animals at both sampling times
d1 d11 d6 
calf X
(control)
calf W
(challenge)
Figure 4 Sequential bone marrow histology of control calf X (upper row) and challenge calf W (lower row) at days 1, 6 and 11.
Examples of erythroid clusters are indicated by blue arrows and examples of megakaryocytes by black arrowheads. Left column: Biopsy
cores at day 1 from challenge calf (W) and control calf (X) contain similar distributions of erythroid clusters and megakaryocytes. Centre column:
By day 6, the numbers of haematopoietic cells (HPC) including megakaryocytes has markedly decreased in the challenge calf, whereas there is an
increased density of HPC in the control calf compared with the earlier time point. Erythroid clusters in the challenge calf are composed mainly of
cells in the later stages of differentiation. Right column: At necropsy on day 11, trilineage hypoplasia with absence of all HPC clusters is found in
the challenge calf whereas there is no change in the control compared with day 6: Bar = 100 μm (applies to all images).
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(based on previous observations of cultures from healthy
calves during protocol development and validation). The
low number of animals used and variation between col-
ony counts precludes statistical analysis of cloning effi-
ciencies for the 24 hour biopsy, however, morphological
assessment was possible (see below). By day 6 marked
differences were observed between the control and chal-
lenge groups in terms of colony counts for all three col-
ony types (Figure 5).
At the 24 hour biopsies, in both control and challenge
animals, CFU-E colonies were clearly visible with a dis-
tinct reddish colour due to hemoglobinisation and were
of similar size and morphology. However for the day 6
biopsies, while CFU-E colonies developed normally in
the control animals, no CFU-E colonies were identified
in the challenge animals. Similarly, for CFU-GM, colony
number and morphology were preserved at 24 hours for
both control and challenge animals. However by day 6,
the number of CFU-GM was markedly reduced in sam-
ples from challenge animals as compared to the controls
(Figure 5).
There was a marked difference between the two
groups with respect to size and morphology of the CFU-
GEMM colonies, in both the 24 hour and 6 day samples
(Figure 6). Colonies from control calves’ biopsies were
composed of a higher number of cells, distributed over a
wider area around the compact centre of the colony,
while colonies from challenge calves’ biopsies were com-
posed of fewer, larger cells and had more compact
centres.
Discussion
This is the first etiopathogenesis study of BNP which
assesses the functionality of BM-HPCs. The results
shown here demonstrate that BNP was induced in
the challenge animals and that functional damage to
the hematopoietic progenitor cells was apparent prior to
the development of clinical signs, gross or histopatho-
logical lesions. As early as 24 hours after colostrum intake,
the CFUs-GEMM were compromised in their colony
forming ability and by day 6 the number of all CFU types
was markedly reduced. This supports the hypothesis that
the main target cell is the pluripotent hematopoietic pro-
genitor cell. In addition, this study further demonstrates
that the more differentiated cells (CFU-E and CFU-GM
precursors) present in the bone marrow are apparently not
compromised at 24 hours post-colostrum ingestion.
Lymphopenia post-colostral challenge has been previ-
ously observed [9,10,12]; therefore in this study we
attempted to determine whether a specific subset of per-
ipheral blood mononuclear cells (PBMC) was depleted.
We failed to demonstrate any subset-specific depletion,
but did observe a tendency for CD25+ve, γδT cell and B
cell percentages to drop and subsequently fail to rise
when compared to control animals. B-cell lymphopoesis
begins in the fetal liver with transition to the bone mar-
row shortly after birth [26]. The observed failure of
B-cell percentages to rise after colostrum ingestion sug-
gests that B lymphocytes may be removed from the
circulation during this transition stage. γδT cells are
enriched at epithelial surfaces as well as being the pre-
0
100
200
300
400
500
600
700
800
900
1000
0
20
40
60
80
100
120
140
160
180
W 24 hours W 6 days Y 24 hours Y6 days X 24 hours X 6 days Z 24 hours Z 6 days
number of CFU-GEMM 
(left axis)
number of CFU-GM  
(left axis) 
number of CFU-E (right  
axis)
CFU-E 
per plate
CFU-GEMM 
and CFU-GM
per plate
Challenge animals Control animals
Animal ID and bone marrow  
biopsy timepoint 
Figure 5 Colony counts in BM-HPC cultures from biopsies taken at 24 hours and 6 days post-colostral challenge. Calves W and Y are
challenge animals, calves X and Z are controls. At 24 hours, no difference is observed between animals/groups in terms of colony counts, though
morphological differences were observed (see text and figure 3). At 6 days post-colostral challenge all three lineages are markedly reduced in
both challenged calves (W and Y) as compared to the control animals (X and Z). No CFU-E were observed in either challenged animal at 6 days.
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eminent blood lymphocytes subpopulation in young
ruminants [27]; migration of γδT-cells from the thymus
toward peripheral tissues increases markedly during fetal
life and after birth [28]. In analogy with B cells, it is
possible that these cells are also removed from the circu-
lation at this critical homing stage. CD25+ve cells repre-
sent activated or regulatory B and T cells, as well as
some thymocytes and myeloid precursors (such as those
which coexpress CD13, CD33, CD34, MY8, and
HLA-DR, and lack CD14 or CD11b being at or near the
myeloblast stage of differentiation [29]). CD25 is also
transiently expressed at a low level during normal B-cell
development (pre-B cell stage in the bone marrow [30]
and at a higher level during a very early stage of T-cell
development in fetal and adult thymus (double negative
stage) [31]. This very early removal of lymphocytes from
the peripheral circulation, taken in association with the
previous demonstration of binding of alloantibodies
[8,14,15] support the hypothesis that one or more com-
mon antigen(s) present on bone marrow HPCs and
lymphocytes are targeted almost immediately after col-
ostrum absorption.
Two groups have recently published evidence demon-
strating the presence of -MHC-class I specific antibodies
on circulating leukocytes of affected calves [14,15].
While the induction of such antibodies during BNP is
clear, specificity for the broadly expressed classical
MHC-I molecules may not be responsible for the disease
syndrome per se as they would be expected to target
cells more widely than the haematopoietic lineages (bone
marrow and peripheral lymphocytes). Our observations
suggest that alloantibodies targeting other common
antigens could be responsible for the bone marrow lesion,
due to the apparent sparing effect on CFU-E and CFU-GM
at the 24 hour biopsy as well as peripheral granulocytes
throughout the clinical progression. Expression of MHC-I
is widespread and includes both CFU-E and CFU-GM in
cattle [23,32] but the presence of MHC-I on bovine
CFU-GEMM, while it would be expected, has not been
confirmed. Possible explanations could include a differ-
ence in the levels of MHC-I expression in the highly ac-
tive CFU-GEMM, a difference in their susceptibility to
damage, or a difference in cell-type specific expression of
an unusual non-classical MHC- I specificity which could
make these cells more sensitive to antibody-dependent
damage (either via ADCC or complement-mediated).
Further studies in this area are required to clarify the
exact mechanism(s).
Conclusion
This study demonstrates the utility of in vitro BM-HPC
culture in the investigation of BNP. This may facilitate
further studies of early pathogenesis, which is not pos-
sible by investigation of natural cases, since once the
clinical features are apparent the bone marrow lesion is
already too advanced to define its pathogenesis.
We show that pluripotent CFU-GEMMs are function-
ally compromised within the first 24 hours post colos-
trum ingestion and that all colony types examined are
damaged by day 6. This method will facilitate in vitro
studies to further characterise the aetiology, maternal
vaccinal responses, colostral antibody titre and specifi-
city in a standardised, non-animal model system. In
addition we show that the profound lymphopenia
Figure 6 Typical CFU-GEMM colonies identified on day 7 of culture in control (left) and challenge (right) calves for 24h (top row) and 6
day (bottom row) post challenge biopsies (x10).
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observed in the early stages of BNP does not appear to
be subset- specific and the differences observed in the
behaviour of B and γδ T cells are probably related to the
inability of the thymus to respond to environmental
pressures by increasing cellular output.
Further development of such in vitro cell culture sys-
tems should improve opportunities to investigate the
functional target of the alloantibodies in BM-HPCs in
BNP and could allow investigation of the potential risk
to other species, including man, of consumption of col-
ostrum or milk from affected cows as well as assessment
of the safety of inactivated vaccines in pregnancy.
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